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Abstract
Coexistence of systemic lupus erythematosus (SLE) should be considered in patients with inflam-
matory bowel disease (IBD) and complex extraintestinal manifestations and the diagnosis of IBD
could be established either before or after the diagnosis of SLE. Differential diagnosis of con-
comitant SLE and IBD is difficult and should always exclude infectious conditions, lupus-like re-
actions, visceral vasculitis and drug-induced lupus.
The underlying mechanism by which 5-ASA/sulphasalazine induces SLE or lupus-like syndromes is
not clear and high awareness for possible predictive factors is demanded for early prevention.
In most cases the symptoms from drug-induced lupus have been reversible after the discontinua-
tion of the drug and response to steroids is favorable. Treatment of patients co-diagnosed with
SLE and IBD may include corticosteroids, immunosupressants and hydroxychloroquine.
In severe lupus and IBD patients cyclophosphamide pulse may be of benefit while infliximab may
be beneficiary in patients with lupus nephritis. However, the role TNFalpha plays in humans with
SLE and IBD is controversial and data on the likely effects of blocking TNFalpha on anti-DNA
autoantibody production is always of interest.
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Inflammatory bowel disease (IBD) is a chronic recurrent disease
characterized by intestinal mucosal inflammation and includes
ulcerative colitis (UC) and Crohn's disease (CD). Almost one
fourth of IBD patients suffer from extra-intestinal manifesta-
tions, including oligoarticular or polyarthicular non-deforming
peripheral arthritis, spondylitis or sacroilitis, episcleritis or
uveitis, erythema nodosum, pyoderma gangrenosum, sclerosing
cholangitis and thromboembolic events. On the other hand,
systemic lupus erythematosus (SLE) is an autoimmune disorder
occurring predominantly in women during reproductive years.
It is a multisystem disease with numerous clinical manifesta-
tions such as skin rashes, photosensitivity, oral ulcers, arthri-
tis, serositis, renal, neurologic and hematologic disorders.
The characteristic immunologic findings include the presence
of antinuclear antibodies (ANAs), anti-DNA, anti-Sm and anti-
phospholipid antibodies.
The coexistence of the IBD and SLE is rare. The coexis-
tence of clinical features of both diseases in a patient repre-
sents a diagnostic challenge. In fact, it is not known whether
IBD and SLE co-occur by chance or by real association and no
data on incidence/prevalence of IBD and SLE co-occurrence
is available.
After reviewing systematically the literature using all
terms relevant to IBD and lupus, we present the gastrointes-
tinal features of SLE, the lupus-like syndrome caused by
drugs used in IBD as well as the coexistence of SLE with IBD
and the treatment that can be used in both entities.12. Systemic lupus erythematosus and
gastrointestinal involvement
Gastrointestinal symptoms are common in systemic lupus
erythematosus (SLE) patients, and more than half of them
are caused by adverse reactions to medications and viral or
bacterial infections. Gastrointestinal manifestations may
overshadow other aspects of the disease and mimic any
type of abdominal condition. Lupus mesenteric vasculitis is
the most common cause, followed by protein-losing enteropa-
thy, acute pancreatitis, serositis (peritonitis) intestinal
pseudo-obstruction and other rare comorbidities such as celiac
disease and inflammatory bowel disease (IBD).2 In an exten-
sive review of the gastrointestinal and hepatic manifestations
of systemic lupus erythematosus only about 10% of patientswith autoimmune hepatitis had lupus and up to 4.7% of pa-
tients with SLE had chronic active hepatitis.3
Some of the more potentially dangerous gastrointestinal
complications of SLE occur in the small and large intestines
secondary to small-vessel vasculitis. This may progress to is-
chemic enteritis and to bowel infarction with bleeding or
perforation and peritonitis. Clinical presentation is variable
and the definite diagnosis of vasculitis may be difficult to es-
tablish because of its insidious and intermittent behavior
that is common prior to the acute event. Abdominal pain,
nausea and vomiting are frequent manifestations of gastro-
intestinal vasculitis.4 The exact incidence of lupus vasculitis
in the gastrointestinal tract is hard to determine. The preva-
lence of intestinal vasculitis has been reported to range from
0.2 to 53% of patients with SLE but clinically apparent bowel
vasculitis occurs in about 2% of SLE patients. Vasculitis in SLE
may involve any part of the gastrointestinal tract from
esophagus to colon though there is a tendency for the vascu-
litis to affect the distribution of superior mesenteric artery.
It is quite rare and almost always accompanied by evidence
of active disease in other organs, although occasionally it
may be the presenting feature of the disease. Lupus enteri-
tis unlike CD and UC, may be complicated by perforation
even when the disease appears to be well controlled.5
Thrombosis of mesenteric vessels associated with the anti-
phospholipid syndrome can give rise to mesenteric ischemia
and bowel infarction. No specific autoantibody is identified
as being associated with this SLE-related gastroenteropa-
thy.5 The peritoneum is the least likely of the serosal linings
to be affected in SLE. Symptoms include rebound tender-
ness, fever, nausea, vomiting and diarrhea leading fre-
quently in surgical intervention.
Imaging studies are helpful in diagnosing SLE-related gas-
troenteropathies. Early nondiagnostic radiographic findings
include thumbprinting, pseudoobstruction and segmental
bowel dilatation. Abdominal CT and arteriography may be
more helpful with diagnosis but a negative arteriogram
does not exclude disease because vasculitis generally in-
volves small arteries.6
Abdominal CT scan may show thickened small bowel loops
with contrast enhancement consistent with small bowel is-
chemia. However, small bowel thickening is not a specific
finding for intestinal vasculitis and may be also associated
with hypoalbuminemia, IBD and gastroenteritis.7
Colon involvement in systemic lupus erythematosus at
barium enema is depicted as the “collar button” type of
737Inflammatory bowel disease and lupus: A systematic review of the literaturepenetrating ulcers and at endoscopy the multiple round- or
oval-shaped discrete ulcers, the so-called “punched-out” ul-
cers with pale mucosa can be found. Differential diagnosis
with ulcerative colitis ulcers in patients with SLE-related
colon involvement is sometimes very difficult. To be more
confident in a definite diagnosis a panel of imaging, endo-
scopic and histological information may be needed. In
lupus cases colon involvement at endoscopy and/or radiolo-
gy is remarkably segmental with focal non-perimetrical dis-
tributed ulcerations and biopsies keep in general the
architectural structure of the mucosa with a remarkable ab-
sence of cell typical in chronic inflammatory conditions.8
Therapy of lupus vasculitis may include high-dose cortico-
steroids (prednisone 1–2 mg/kg/day) or pulse therapy with
methylprednisolone 1 g/day for 3 days and azathioprine/6-
mercaptopurine. Intestinal rest with parenteral nutrition,
prokinetics and antibiotics may be of help.3 Cyclophospha-
mide pulse therapy 0.75–1 g/m2 may be used in refractory
cases.9
3. Concomitant diagnosis of IBD and SLE
Concomitant diagnosis of IBD and SLE is rare and IBD may
occur either before or after SLE diagnosis (Table 1). Al-
though a chance occurrence cannot be excluded it is possible
that both conditions share some genetic or immunological
defects. However, data on common genetic susceptibility
between SLE and CD is controversial.10,11 In addition, certain
medications used for treating IBD may cause drug-induced
lupus.Table 1 Overview of patients with concomitant diagnosis of infla
Author Year Type of study IBD diagnosis L
Fujimori et al.12 1987 Case CD S
Su et al.13 2008 Case CD S
Johnson et al.14 1985 Case CD S
Sanchez-Burson et al.15 2004 Case CD S
Toulemonde P et al.16 2001 Case CD S
Mornet et al.17 1973 Case CD S
Principi et al.18 2004 Case CD S
Sugimoto et al.19 1989 Case CD S
Nishida Y et al.20 1998 Case CD S
Ashworth et al.21 1992 Case CD C
Shafer et al.22 1970 Case CD S
Dubrow et al.23 1966 Case CD S
Shimizu et al.24 1999 Case CD? S
Buchman et al.25 1995 Case CD? S
Tsuchiya et al.8 1975 Retrospective UC S
Sultan et al.4 1999 Retrospective UC S
Font et al.32 1988 Case UC S
Medeiros et al.33 2009 Case UC S
Bourikas et al.34 2008 Case UC S
Nieradko-Iwanicka et al.35 2006 Case UC S
Sugiyama et al.36 1996 Case UC S
Garcia-Porrua et al.37 1998 Case UC S
Koutroubakis et al.38 1998 Case UC S
Ishikawa et al.39 1995 Case UC S
Stevens et al.40 1994 Case UC S
Papi et al.41 1995 Case UC SAccording to a referral center study the overall preva-
lence of concomitant ulcerative colitis (UC) diagnosis is
0.4% of SLE patients. The concurrence of SLE and Crohn's
disease (CD) is even more rare.4
Only few cases of SLE-related to UC have been reported so
far, and numbers of SLE related CD are even less including
some cases with presumable co-existence of the two diseases.
The majority of those patients have excellent response to
steroids combined with hydroxychloroquine or/and azathio-
prine. However, some patients with CD may have life-
threatening gastrointestinal bleeding and some may need
high dosage methylprednisolone for maintenance therapy.
The prognosis of SLE-related IBD is usually good.
4. Crohn's disease and lupus
The concurrence of SLE and CD is rare. There are very few
case reports of the co-existence of these two diseases
while data regarding common genetic susceptibility be-
tween SLE and CD is controversial.4 A study did not find evi-
dence that the Crohn's disease-associated mutations on
CARD15 contributed to SLE susceptibility.10 A pooled analy-
sis of existing published and unpublished data in 1305 cases
of SLE genotyped for the CARD15 risk alleles suggests that
only the CARD15 (908R) IBD risk allele may have a strong ef-
fect on risk of SLE.11
In total nine cases12–20 of CD and SLE and one with CD and
subacute cutaneous lupus erythematosus21 have so far been
described, all in young individuals. One of these cases was
complicated with massive lower gastrointestinal bleeding,13mmatory bowel disease (UC and CD) and lupus erythematosus.
upus diagnosis Remarks
LE Co-existing Sjögren's syndrome
LE Manifested with massive intestinal bleeding
LE
LE
LE CD followed SLE diagnosis
LE
LE Concomitant lupus nephritis
LE Lupus nephritis responded to infliximab
LE Family with 3 members diagnosed with CD
utaneous lupus
LE?
LE?
LE Differential diagnosis with lupus enteritis
LE Differential diagnosis with lupus enteritis
LE Clinical overview of 35 cases of UC/SLE
LE UC in 0.4% of all SLE patients
LE
LE
LE Concomitant non-Hodgkin lymphoma
LE Lupus nephritis
LE Lupus nephritis
LE
LE
LE
LE Concommitant primary sclerosing cholangitis
LE? Dural sinus thrombosis
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drome and CD were co-existing12 and finally one case was
of familial CD with three family members affected.20
In the majority of these cases CD was the preceding diag-
nosis. However, in some cases CD diagnosis also followed16,18
SLE diagnosis. Two of the eight cases were complicated by
lupus nephritis18,19 and one of them showed favorable
renal response to infliximab.19
There have been two additional reports22,23 of patients
with presumed coexistence of SLE and CD, although patho-
logic information was not available. The first was a report
of a 20-year-old man who presented with acute abdominal
pain, anemia, leukopenia, and an abnormal urinary sedi-
ment.22 A localized area of non-specific ileitis was found at
laparotomy. Patient also demonstrated a false-positive test
for syphilis, circulating anticoagulant, abnormal serum pro-
teins, and cryoglobulins. No definite diagnosis of either
Crohn's disease or SLE could be made. The second report de-
scribes a 35-year-old man with an established diagnosis of
SLE with pleuritis, arthralgia, hematuria and proteinuria,
and positive lupus cells who developed abdominal pain and
was found to have two areas of edema and red-purple dis-
coloration in the distal ileum associated with narrowing of
the lumen.23
The differentiation of CD from SLE gastrointestinal in-
volvement may be difficult. In fact, cases with inflammatory
bowel diseases like CD could show similar clinical signs and
symptoms to SLE, and in some cases of CD might fulfill
some of the classification of criteria for SLE.24,25
Gastrointestinal symptoms, laboratory studies, and radio-
graphic findings may appear similar between the two
diseases. The correct diagnosis has important treatment
and prognostic implications.
Furthermore, diagnosis of such rare cases needs always to
exclude relative co morbidities or overlapping features of
similar pathogenic entities and always requires a plan for op-
timal management of both systemic diseases.
Two cases in SLE patients that mimic IBD have been also
reported. One case of a patient with strongyloidiasis26 and
one of CMV infection mimicking CD of the terminal ileum.27
In this case, ganciclovir therapy was effective in resolving
his symptoms and normalizing his ileal mucosa.
The presence of phospholipid-binding antibodies could be
a sign of vascular alterations that are potentially thrombo-
genic per se, and their predictive value with respect to the
specific inflammatory syndrome of Crohn's disease is an im-
portant phenomenon.27 Two cases with antiphospholipid
syndrome manifested by ischemic stroke28 and thrombosis29
in Crohn's disease have been reported. There may be a pos-
sible association between antiphospholipid syndrome and
hypercoagulable state in Crohn's disease.5. Ulcerative colitis and lupus
The association between UC and SLE is rare. Since Brown et
al.30 reported the first UC and SLE case in 1956, Dubois and
Tuffaneli reported that the incidence of UC in 520 cases of
SLE was 0.4% (only two cases)31 and in October 1975 Tsu-
chiya et al.8 reported that they had found so far 35 cases
of SLE with UC reported in the literature including their
own case. Our thorough search in the literature resulted ineleven additional cases from 1988 until today.32–40 Another
patient from this list developed hypocomplementemic urti-
carial vasculitis syndrome, a year prior to the onset of ulcera-
tive colitis. Ten years later, primary sclerosing cholangitis and
the antiphospholipid syndrome developed concomitantly.40
In these series, one case of patient with small bowel per-
foration due to concomitant non-Hodgkin-lymphoma oc-
curred.34 The same list includes three cases of lupus
nephritis.35,36 Among those three cases, one was with dif-
fuse proliferative lupus nephritis36 and two with chronic glo-
merulonephritis and mild renal failure respectively.35 In the
first case nephrotic syndrome partially improved with corti-
costeroid therapy combined with cessation of sulfasalazine.
An additional case of severe UC, dural sinus thrombosis and
lupus anticoagulant could be probably added in this list.41
The patient was successfully treated with osmotic agents,
prophylactic anticonvulsant, and antiplatelet therapy, com-
bined with i.v. steroids.
In some of the SLE cases endoscopic featureswere different
from those of ulcerative colitis. Multiple “punched out” ulcers
with pale mucosa were not seen in UC but in ischemic colitis
and in the colonic involvement of vasculitis and SLE. In other
cases endoscopic findings were compatible with those of ul-
cerative colitis.
6. 5-ASA compound-induced lupus in IBD
Sulphasalazine-induced lupus syndrome has been reported
several times in UC42–45 including children46 as well as in
CD patients.47
Although 5-ASA preparations used to treat inflammatory
bowel disease are reported to have fewer side effects than
sulphasalazine, increased clinical use of these compounds
including mesalazine has resulted in some reports of signifi-
cant side effects including those fulfilling the criteria of a
drug-induced lupus-like syndrome.48–52
The clinical pattern can be presented with SLE or SLE-like
syndrome and may manifest with antinuclear antibodies
(ANA), anti-double-stranded DNA antibodies (anti-dsDNA),
anti-histone antibodies (anti-histones) and a variety of symp-
toms including serositis, pulmonary parenchymal, joint symp-
toms and skin rush. Severe clinical manifestations are those of
general vasculitis affecting the central and peripheral nervous
system and lungs and may have a fatal evolution. Diagnosis
may be typical but in some atypical cases the connection
with medication can be ascertained by re-exposition.
Features which may discriminate between sulphasalazine-
induced lupus and the association of IBD with idiopathic SLE
are the presence of low complement levels (as drug-induced
lupus is only rarely associated with low complement levels),
presence of different types of autoantibodies which occur in
idiopathic SLE [antibodies to C1q, anticardiolipin antibodies
(which occur in 10–30% of SLE patients), anti-Ro and anti-La
antibodies] and HLA status as HLA DR3 is associated with idio-
pathic disease, whereas DR4 occurs in drug-induced lupus.53
Therapy includes sulphasalazine/5-ASA discontinuation
and administration of corticosteroids. In severe cases cyclo-
phosphamide can be used. Leukopenia, anemia, and high ti-
tres of antinuclear and DNA antibodies return to normal
after withdrawal of the drug; resolution of symptoms, usual-
ly occurs over a period of four to six months.
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in sulphasalazine-induced systemic lupus erythematosus
slow acetylator genotype (enzyme N-acetyltransferase 2)
and HLA haplotypes seem to predict disease induction. In ad-
dition, persistent SLE and development of nephritis were
noted in patients with long duration of treatment and high
cumulative dose of sulphasalazine (N1000 g).
Sulphasalazine-induced lupus syndrome in ulcerative coli-
tis has been reported in seven42,44–46 patients including one
child46 among them.
In one of these patients42 with salazosulfapyridine-
induced lupus syndrome the connection with medication
was ascertained by re-exposition.
In another patient44 pneumonitis, bilateral pleural effu-
sions, echocardiographic evidence of cardiac tamponade,
and positive autoantibodies were developed in the absence
of joint symptoms. After cessation of the sulfasalazine and
completion of a six-week course of corticosteroids, these
problems resolved over a period of four to six months.
Sulphasalazine-induced lupus syndrome in CD has been
reported in four20,47–49 patients. In one of them sulfasalazine/
mesalazine-induced lupus syndrome resulted in a fatal evolu-
tion despitemethylprednisolone and cyclophosphamide use.487. Anti-TNFα therapies and lupus in IBD
Induction of autoimmunity in the form of antinuclear anti-
bodies and/or anti-dsDNA antibodies has been often seen in
IBD patients treated with TNFalpha inhibitors.
On the other hand, the role TNFalpha plays in SLE is con-
troversial and data on the likely effects of blocking TNFalpha
on anti-DNA autoantibody production is always of interest.54
In CD patients autoantibody formation like ANA and anti-
dsDNA may occur in up to 53% of cases. According to the
same study autoantibody formation may occur in up to 42%
of patients during short-term infliximab treatment for
Crohn's disease. Of interest 8% of these patients were posi-
tive before infliximab treatment.55
Despite the significant prevalence of such autoantibodies
(ANA and anti-dsDNA in 53% and 35% of infliximab-treated
patients with CD, respectively), those antibodies are not
generally associated with clinical signs of autoimmunity56
and there is no indication for monitoring in patients who
have no symptoms.57
There is no clear explanation for this high prevalence of
those autoantibodies. We may hypothesize that the apopto-
sis induced by anti-TNFs, infliximab and adalimumab, is ef-
fectively a DNA immunization, hence leading to at times
high titers of ANA without illness associated with them.
Patients on anti-TNFα therapies may rarely present
lupus-like syndrome58–60 or cutaneous lupus.61 True cases
of SLE in IBD patients treated either with infliximab62,63 or
adalimumab64,65 have been rarely reported.
In a prospective study investigating the occurrence of an-
tinuclear antibodies in 125 consecutive CD patients treated
with infliximab the cumulative incidence of ANA was 56.8%
after 24 months. Antinuclear antibodies persisted up to
1 year after the last infusion, and only a few patients be-
came seronegative. Two patients developed drug-induced
lupus erythematosus. Antinuclear antibodies were associated
with the female sex and skin manifestations.62 According toMayo clinic experience in 500 patients treated with infliximab
and followed-up for 17 months only three patients developed
drug-induced lupus.63 The safety profile of adalimumab in pa-
tients with CD was similar to that of other TNF antagonists in
CD populations.64
Cases were reversible and manageable upon discontinua-
tion of treatment and ANA monitoring should not be routine-
ly performed in anti-TNFα-treated patients with no clinically
relevant symptoms.66–68
Adalimumab safety in CD clinical trials including induc-
tion trials (CLASSIC-I, GAIN), open-label period of CHARM,
double blind maintenance (CLASSIC-II, CHARM) and all CD
clinical trials including open-label extension, demonstrated
only 3 lupus-like cases. Of note is the fact that none of the
patients met the strict diagnostic criteria for DILE and pa-
tients experience a clinical improvement 6–12 weeks
afterwards.69–72
The relative rarity of cases with systemic DILE due to ada-
limumab compared to those receiving infliximab or etaner-
cept is still debatable.64,73
According to recent experience from a Spanish IBD group
DILE seems more prevalent in adalimumab-treated patients
compared to the infliximab-treated ones.73 By contrast, in
the CLASSIC-II trial no cases of DILE were noted.64
Of interest, until 2007 none such DILE case had been
reported to the Netherlands Pharmacovigilance Centre. In
the same study, it has been hypothesized that adalimumab
may boost the infliximab-induced mechanisms for anti-
dsDNA development. In fact, increased cytokine and anti-
dsDNA levels accompany SLE development upon infliximab–
adalimumab conversion.74
The question whether the development of drug-related
lupus is a contraindication for switching from one TNFα in-
hibitor to another still remains unanswered.75
Finally, certolizumab is not supposed to induce apoptosis,
but there has been a report of a recurrent DILE following
3 months of therapy with certolizumab as a second anti-
TNF agent after infliximab failure.76 In a study of 180 IBD pa-
tients treated with anti-TNF antibodies (infliximab or adali-
mumab, or infliximab and adalimumab consecutively)
factors predicting the development of lupus-like syndrome
were analyzed. IBD patients of higher age treated with
anti-TNF-α antibodies are at increased risk for development
of ANA and lupus-like syndrome, while concomitant immuno-
suppressive therapy showed a protective effect.77
A logical clinically relevant approach is that in cases of
ANA positive patients who are switched from one anti-
TNFα agent to another no specific caution or follow up is
necessary except in those rare cases in which the patient
was previously diagnosed with DILE or ‘lupus-like’ syndrome
while receiving the initial anti-TNFα therapy.78
Future studies and larger experience are of great impor-
tance in order to define the best diagnostic and treatment
strategies in these complicated cases of complex autoimmu-
nity (Fig. 1).8. Conclusions• IBD and SLE are multisystemic autoimmune related diseases. IBD
predominantly affects gastrointestinal tract, while SLE may also
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Fig. 1 Algorithm to confirm either systemic lupus erythematosus (SLE) or drug-induced lupus (DILE) and their respective manage-
ments in patients with inflammatory bowel disease and lupus symptoms.
740 K.H. Katsanos et al.present gastrointestinal involvement such as: vasculitis, pancreati-
tis and protein-losing enteropathy.
• Concomitant diagnosis of IBD and SLE is rare.
• Drug-induced lupus in IBD has been recognized. Sulphasalazine or
5-ASA may present a lupus-like syndrome with serositis, joint in-
volvement, skin rashes and ANAs, anti-dsDNA and anti-histones
positivity. Treatment includes discontinuation of the offending
drug and administration of corticosteroids.
• Induction of autoimmunity in the form of ANAs and/or anti-
dsDNA antibodies has been often seen in IBD patients treatedwith TNFα inhibitors although the occurrence of true lupus or
lupus-like syndrome is rare.
• Coexistence of IBD and SLE is a clinical and therapeutic challenge
for the clinicians.Conflict of interest
None.
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